FNY Managed Accounts’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

FNY Managed Accounts’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-500	Closed	-$2K	–	996
2017 Q4	$2K	Sell	500 -2,700	-84%	-$11.7K	﹤0.01%	545
2017 Q3	$14K	Buy	+3,200	New	+$13K	0.02%	409

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FNY Managed Accounts's OMED Position: Q1 2018 in Review

FNY Managed Accounts sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 500 shares — an estimated $2K sold.

FNY Managed Accounts first reported a position in OMED in Q3 2017 and held it in 2 quarters. The position peaked at $14K in Q3 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

FNY Managed Accounts reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
FNY Managed Accounts sold 500 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2K.
FNY Managed Accounts first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
FNY Managed Accounts's OncoMed Pharmaceuticals, Inc. position peaked at $14K in Q3 2017.
66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.